Volume 11, Issue 2

MASLD: Diagnosis, Staging, and Treatment.

In this issue:

MASLD (metabolic dysfunction associated steatotic liver disease) is the most common liver disease worldwide. It can lead to liver fibrosis and cirrhosis, and has been independently associated with a higher risk of cardiovascular events.  

MASLD affects approximately 40% of individuals with HIV. Due to common concomitant conditions like obesity, diabetes, and hyperlipidemia, along with the chronic immune activation inherent with HIV infection, data has shown that people with HIV tend to experience faster fibrosis progression than people without HIV.  

In this issue of eHIV Review, Kara Wegermann MD, a MASLD specialist from the Duke University School of Medicine, explains the need for accurate and early MASLD diagnosis, and the evidence-based treatment options for PWH with MASLD in both its early and later stages.  

Learning objective:

Appraise the efficacy of diagnostic and treatment options for MASLD for people living with HIV. 

Author:

Kara Wegermann, MD
Kara Wegermann, MD

Assistant Professor of Medicine
Division of Gastroenterology, Department of Medicine
Duke University School of Medicine
Durham, NC


Program Directors:

Justin Alves, RN, FNP-BC, ACRN, CARN, CNE

Nurse Educator
Boston Medical Center
Boston, MA
(he/him/his)

Matthew Spinelli, MD, MAS

Associate Professor
HIV, ID, and Global Medicine
Zuckerberg San Francisco General Hospital
San Francisco, CA
(he/him/his)

Ethel D. Weld, MD, PhD

Associate Professor of Medicine, Physiology, Pharmacology & Therapeutics
Johns Hopkins School of Medicine
Baltimore, MD
(she/her/hers)

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: August 18, 2026
Expiration date: August 17, 2028